2012: A Good, Bad or Ugly Year for Servier? - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

2012: A Good, Bad or Ugly Year for Servier?
The scandal surrounding Servier's diabetes drug, Mediator, continues to unravel in France and could have implications for the whole pharmaceutical industry as the country scrutinises its regulatory systems.

Pharmaceutical Technology Europe
Volume 24, Issue 2


1. E. Lanez, "Mediator : l'effarante boîte à mensonges" (Le Point.fr, 2011) http://www.lepoint.fr, accessed Jan. 9, 2012.

2. B. Casassus, "With New Law, France Revamps Drug Approval" (Science, 2011). http://news.sciencemag.org/, accessed Jan. 9, 2012.

3. Servier, "Research is as vital as being an industry " (Servier website, 2011). http://www.servier.com/, accessed 9 Jan., 2012.

4. J. Upton, "Servier: patience and passion," Pharmaceutical Executive Europe (November 2008).

5. Focus Reports, "Interview—Jacques Servier" (2011). http://www.pharma.focusreports.net/, accessed 9 Jan., 2012.

6. K. Grogan, "Servier signs cancer deal with Sweden's BioInvent" (Pharma Times, 2012). http://www.pharmatimes.com/, accessed Jan. 9, 2012.

7. European Biotechnology Science & Industry News "Galapagos gets €4 million in alliance with Servier" (2011). http://www.eurobiotechnews.eu, accessed 9 Jan., 2012.

8. N. Jessop, Pharm. Technol. Eur. 23 (3), 14–18 (2011).

9. Le Point.fr, "Mediator, un jugement pour 2012?" (2011). http://www.lepoint.fr, accessed Jan. 9, 2012.

10. S. Sayare, "Scandal Over Mediator, a French Weight-Loss Drug, Prompts Calls for Wide Changes" (New York Times, 2011). http://www.nytimes.com/, accessed Jan. 9, 2012

11. Assemblée Nationale (2011). http://www.assemblee-nationale.fr/13/rap-info/i3552.asp, accessed Jan. 11, 2012

12. InPharm, "2011 Year In Review" (2012). http://www.inpharm.com/, accessed Jan. 9, 2012.

13. Le Nouvel Observateur, "Mediator: la cour rejette le regroupement des procédures" (2011). http://tempsreel.nouvelobs.com/, accessed Jan. 11, 2012.


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
Source: Pharmaceutical Technology Europe,
Click here